Nucor earnings beat by $0.08, revenue fell short of estimates
LONDON - GSK plc (LSE/NYSE: GSK) announced the appointment of Dr Gavin Screaton as a Non-Executive Director, effective May 1, 2025. Dr Screaton, currently serving as Head of the Medical (TASE:BLWV) Sciences Division at the University of Oxford, will be succeeding Dr Jesse Goodman, who is retiring after nine years on the GSK Board.
Dr Screaton’s appointment comes as part of a planned succession following Dr Goodman’s departure after the company’s Annual General Meeting in May 2025. With a distinguished career in immunology and infectious diseases, Dr Screaton’s expertise aligns with GSK’s scientific research focus areas. He holds several prestigious positions, including Fellow of the Academy of Medical Sciences and the Royal College of Physicians, and is a co-founder of RQ Bio.
Upon joining, Dr Screaton will be a member of both the GSK Board Science Committee and the Corporate Responsibility Committee. His appointment is expected to bring a valuable perspective to the Board, especially in public health, a domain critical to GSK’s operations.
Sir Jonathan Symonds, Chair of GSK, expressed the company’s enthusiasm about Dr Screaton joining the Board, highlighting his deep expertise in fields that are central to GSK’s scientific endeavors. Sir Symonds also acknowledged Dr Goodman’s significant contributions to the company, particularly in infectious diseases, regulation, and public health.
The Nominations & Corporate Governance Committee led the search for Dr Screaton’s appointment, utilizing an external search firm. Dr Screaton has been determined independent in accordance with the UK Corporate Governance Code and will receive an annual fee of £122,258, with an additional £30,000 for his scientific and medical expertise.
The Board, as of May 1, 2025, will include a diverse group of executives and non-executive directors, with Dr Screaton being the latest addition to this team.
GSK is a global biopharma company dedicated to advancing the field of medicine and technology to preemptively tackle diseases. This news is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.